Compounds > atrasentan
Page last updated: 2024-09-04

atrasentan and mdv 3100

atrasentan has been researched along with mdv 3100 in 1 studies

Compound Research Comparison

Studies
(atrasentan)		Trials
(atrasentan)		Recent Studies (post-2010)
(atrasentan)		Studies
(mdv 3100)		Trials
(mdv 3100)		Recent Studies (post-2010) (mdv 3100)
358411081,5461821,502

Protein Interaction Comparison

ProteinTaxonomyatrasentan (IC50)mdv 3100 (IC50)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)3
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)3
Prostate-specific antigenHomo sapiens (human)0.13
Androgen receptorHomo sapiens (human)0.8644
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)3
Androgen receptorRattus norvegicus (Norway rat)0.8238
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)3
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)1.26
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)3
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)3
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)3

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ1

Reviews

1 review(s) available for atrasentan and mdv 3100

ArticleYear
Novel therapies for metastatic castrate-resistant prostate cancer.
    Journal of the National Cancer Institute, 2011, Nov-16, Volume: 103, Issue:22

    Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays

2011